Effects of bevacizumab on microvessel density and endothelial cell proliferation levels in patients with colorectal liver metastases

Trial Profile

Effects of bevacizumab on microvessel density and endothelial cell proliferation levels in patients with colorectal liver metastases

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top